1. Academic Validation
  2. Enteric RET inhibition attenuates gastrointestinal secretion and motility via cholinergic signaling in rat colonic mucosal preparations

Enteric RET inhibition attenuates gastrointestinal secretion and motility via cholinergic signaling in rat colonic mucosal preparations

  • Neurogastroenterol Motil. 2019 Apr;31(4):e13479. doi: 10.1111/nmo.13479.
John P Russell 1 Ehsan Mohammadi 2 Casey Ligon 2 Rocco Latorre 2 Anthony C Johnson 2 Bao Hoang 3 David Krull 3 Melisa W-Y Ho 1 Hilary S Eidam 1 Michael P DeMartino 1 Mui Cheung 1 Allen I Oliff 1 Sanjay Kumar 1 Beverley Greenwood-Van Meerveld 2
Affiliations

Affiliations

  • 1 Virtual Proof of Concept Discovery Performance Unit, GlaxoSmithKline, King of Prussia, Pennsylvania.
  • 2 Oklahoma Center for Neuroscience, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
  • 3 Exploratory Biomarker Assay Group, GlaxoSmithKline, Collegeville, Pennsylvania.
Abstract

Background: The expression of RET in the developing enteric nervous system (ENS) suggests that RET may contribute to adult intestinal function. ENS cholinergic nerves play a critical role in the control of colonic function through the release of acetylcholine (ACh). In the current study, we hypothesized that a RET-mediated mechanism may regulate colonic ion transport and motility through modulation of cholinergic nerves.

Methods: The effect of RET inhibition on active ion transport was assessed electrophysiologically in rat colonic tissue mounted in Ussing chambers via measurements of short circuit current (Isc) upon electrical field stimulation (EFS) or pharmacologically with cholinergic agonists utilizing a gastrointestinal (GI)-restricted RET Inhibitor. We assessed the effect of the RET Inhibitor on propulsive motility via quantification of fecal pellet output (FPO) induced by the acetylcholinesterase inhibitor neostigmine.

Key results: We found that enteric ganglia co-expressed RET and choline acetyltransferase (ChAT) transcripts. In vitro, the RET kinase inhibitor GSK3179106 attenuated the mean increase in Isc induced by either EFS or carbachol but not bethanechol. In vivo, GSK3179106 significantly reduced the prokinetic effect of neostigmine.

Conclusion and inferences: Our findings provide evidence that RET-mediated mechanisms regulate colonic function by maintaining cholinergic neuronal function and enabling ACh-evoked chloride secretion and motility. We suggest that modulating the cholinergic control of the colon via a RET Inhibitor may represent a novel target for the treatment of intestinal disorders associated with increased secretion and accelerated GI transit such as irritable bowel syndrome with diarrhea (IBS-D).

Keywords

RET; cholinergic; enteric nervous system; irritable bowel syndrome; motility; secretion.

Figures
Products